{
  "id": 477664,
  "title": "Jazz bets on epilepsy again by acquiring Actio for $820M upfront",
  "url": "https://urgent.news/2026/08/10/jazz-bets-on-epilepsy-again-by-acquiring-actio-for-820m-upfront",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-10T13:45:18.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/jazz-bets-on-epilepsy-again-by-acquiring-actio-for-820m-upfront/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Jazz Pharmaceuticals will buy Actio Biosciences for $820 million upfront and up to $500 million more if certain milestones are met for its ultra-rare epilepsy drug. The deal further solidifies Jazz’s ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}